SCHEMBL16633148

SCHEMBL16633148

N#Cc1cc2cccc(Br)n2c1

nearest known ligand 0.37

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CHRNA7 P36544 1/20 0.35
MAOA P21397 1/20 0.32
MAOB P27338 1/20 0.32
TSHR P16473 1/20 0.32
ENPP2 Q13822 1/20 0.32
MEN1 O00255 1/20 0.31
TTR P02766 1/20 0.31
ALB P02768 1/20 0.31
KMT2A Q03164 1/20 0.31
CYP11B2 P19099 1/20 0.31
GSK3B P49841 2/20 0.31
DRD2 P14416 1/20 0.31
DRD3 P35462 1/20 0.31
GRM5 P41594 2/20 0.31
EGLN2 Q96KS0 1/20 0.31
ELANE P08246 1/20 0.30
DDB1 Q16531 1/20 0.30
CRBN Q96SW2 1/20 0.30
CLK4 Q9HAZ1 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17331660 0.78 HRH3 (0.36) CHRNA7TSHRENPP2DRD2DRD3
SCHEMBL1994209 0.65 ALDH1A1 (0.43) CHRNA7MAOAMAOBTSHRMEN1
SCHEMBL3587001 0.64 ALDH1A1 (0.36) MAOAMAOB
SCHEMBL16252847 0.64 MAOB (0.37) CHRNA7MAOAMAOBMEN1TTR
SCHEMBL99039 0.60
SCHEMBL29358412 0.60
Water SCHEMBL27994505 0.60 ENPP2 (0.48) MAOAMAOBTSHRENPP2MEN1
SCHEMBL2817154 0.60 TSHR (0.61) TSHRENPP2GSK3BDRD2DRD3
SCHEMBL9289 0.60 TSHR (0.61) TSHRENPP2GSK3BDRD2DRD3
Water SCHEMBL28137572 0.60 TSHR (0.61) TSHRENPP2GSK3BDRD2DRD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9382245-B2 Compounds and methods for treating HIV infections YALE UNIVERSITY (US) 2016-07-05 US disclosed
US-9382245-B2 Compounds and methods for treating HIV infections YALE UNIVERSITY (US) 2016-07-05 US disclosed
US-9382245-B2 Compounds and methods for treating HIV infections YALE UNIVERSITY (US) 2016-07-05 US disclosed
US-20150105351-A1 COMPOUNDS AND METHODS FOR TREATING HIV INFECTIONS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2015-04-16 US disclosed
US-20150105351-A1 COMPOUNDS AND METHODS FOR TREATING HIV INFECTIONS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2015-04-16 US disclosed
US-20150105351-A1 COMPOUNDS AND METHODS FOR TREATING HIV INFECTIONS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2015-04-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150105351-A1 COMPOUNDS AND METHODS FOR TREATING HIV INFECTIONS POLM, POLRMT, DHFR CHRNA7 4703/4885MAOA 1754/4885MAOB 1251/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.